|

SCTC21C Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • Sinocelltech Ltd.2

Indications

  • Cancer2
  • Relapsed or Refractory Hematologic Malignancies1
  • Multiple Myeloma (MM)1

Other2 trials

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Phase 1
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.